Meta-Analysis and Quality of Evidence in the Economic Evaluation of Drug Trials
- 1 April 1992
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 1 (4), 282-292
- https://doi.org/10.2165/00019053-199201040-00005
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Quality of Life Instruments in the Evaluation of New DrugsPharmacoEconomics, 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.1992
- Quality adjusted survival analysisStatistics in Medicine, 1990
- Blood pressure, stroke, and coronary heart disease *1Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution biasThe Lancet, 1990
- Considerations for the meta-analysis of randomized clinical trialsControlled Clinical Trials, 1989
- Confronting publication bias: A cohort design for meta‐analysisStatistics in Medicine, 1987
- Application of statistical decision theory to treatment choices: Implications for the design and analysis of clinical trialsStatistics in Medicine, 1986
- Estimators of the Mantel-Haenszel Variance Consistent in Both Sparse Data and Large-Strata Limiting ModelsBiometrics, 1986
- How to read clinical journals: V: To distinguish useful from useless or even harmful therapy.1981
- Bias in analytic researchJournal of Chronic Diseases, 1979